Covered recipient · General Payments record
JEFFREY P TILLINGHAST
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$7,914.51
153 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $4,641.69 | 14 |
| Food and Beverage | $3,266.59 | 138 |
| Education | $6.23 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,909.80 | 30 |
| Chiesi USA, Inc. | $1,692.01 | 3 |
| AstraZeneca UK Limited | $1,541.34 | 8 |
| GlaxoSmithKline, LLC. | $355.79 | 27 |
| Takeda Pharmaceuticals U.S.A., Inc. | $212.54 | 21 |
| Regeneron Healthcare Solutions, Inc. | $184.10 | 6 |
| GENZYME CORPORATION | $172.64 | 10 |
| PFIZER INC. | $134.90 | 13 |
| Amgen Inc. | $80.56 | 4 |
| Pharming Healthcare, Inc. | $77.57 | 3 |
| Merck Sharp & Dohme LLC | $68.49 | 3 |
| Novartis Pharmaceuticals Corporation | $61.40 | 3 |
| CSL Behring | $59.15 | 2 |
| Grifols USA, LLC | $58.75 | 3 |
| kaleo, Inc. | $55.55 | 4 |
| Mylan Specialty L.P. | $54.35 | 3 |
| AbbVie Inc. | $52.15 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $44.95 | 2 |
| Novo Nordisk Inc | $19.67 | 1 |
| Optinose US, Inc. | $18.64 | 1 |
| Teva Pharmaceuticals USA, Inc. | $15.72 | 1 |
| Incyte Corporation | $15.43 | 1 |
| Otsuka America Pharmaceutical, Inc. | $14.54 | 1 |
| Exact Sciences Corporation | $14.47 | 1 |
Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JEFFREY P TILLINGHAST
NPI 1447393301 · CMS profile ID 65100
Allopathic & Osteopathic Physicians / Allergy & Immunology
SAINT LOUIS, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JEFFREY P TILLINGHAST, NPI 1447393301, CMS profile ID 65100. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JEFFREY P TILLINGHAST, NPI 1447393301, CMS profile ID 65100. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JEFFREY P TILLINGHAST, NPI 1447393301, CMS profile ID 65100, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–153 of 153 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1447393301?year=2023&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
153 matching records · $7,914.51 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–153 of 153.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.14 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997003351 | CMS |
| GlaxoSmithKline, LLC. | $19.45 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1002579849 | CMS |
| Mylan Specialty L.P. | $13.90 | 01/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1039060071 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,407,897.52 | 161 |
| PY2024 | Principal investigator | $2,577,229.58 | 370 |
| PY2023 | Principal investigator | $1,820,825.73 | 287 |
| PY2022 | Principal investigator | $1,679,702.14 | 114 |
| PY2021 | Recipient | $2,640.00 | 2 |
| PY2021 | Principal investigator | $610,606.06 | 108 |
| PY2020 | Principal investigator | $870,068.70 | 73 |
| PY2019 | Recipient | $87.86 | 1 |
| PY2019 | Principal investigator | $1,763,849.37 | 81 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
161 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $3,990.00 | 12/19/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664287 |
| Principal investigator 1 | Verona Pharma, Inc. | $16,083.99 | 12/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891971 |
| Principal investigator 1 | Verona Pharma, Inc. | $250.00 | 12/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891991 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,126.68 | 12/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045922 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,524.30 | 12/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045924 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,126.67 | 12/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045926 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,893.50 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190308822 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,004.10 | 11/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109555 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $133.92 | 11/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045928 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $229.68 | 11/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045936 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $90.93 | 11/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046206 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $45.16 | 11/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190308820 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,988.76 | 11/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891969 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,664.77 | 10/17/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192108140 |
| Principal investigator 1 | Verona Pharma, Inc. | $23,765.36 | 10/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891967 |
| Principal investigator 1 | Verona Pharma, Inc. | $50.00 | 10/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891987 |
| Principal investigator 1 | Verona Pharma, Inc. | $850.00 | 10/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891989 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $71.96 | 10/10/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045818 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $146.78 | 10/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190308824 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,016.00 | 10/02/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192163428 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $38,384.24 | 10/01/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046220 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $71.96 | 09/26/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045816 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,988.76 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891851 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 09/10/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601468 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,572.70 | 09/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192163424 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $40.50 | 08/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190311031 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $107.94 | 08/15/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045814 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $993.16 | 08/15/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046222 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $761.00 | 08/14/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109514 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,978.50 | 08/13/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109527 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,587.78 | 08/08/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109541 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $72,071.00 | 08/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart | No dispute reported | 06/30/2026 | 1185547025 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $56,231.55 | 08/06/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046218 |
| Principal investigator 1 | Verona Pharma, Inc. | $10,000.00 | 07/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891879 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,000.00 | 07/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891881 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,031.19 | 07/21/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192108126 |
| Principal investigator 1 | Genentech, Inc. | $188.00 | 07/18/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664283 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,215.00 | 07/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine | No dispute reported | 06/30/2026 | 1185547035 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $71.96 | 07/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045812 |
| Principal investigator 1 | CIPLA USA INC. | $109.47 | 07/02/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER, LLC | A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. | No dispute reported | 06/30/2026 | 1254932247 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 07/02/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601464 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 07/01/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045810 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $35.98 | 06/20/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244045808 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,353.10 | 06/18/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192163409 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207633 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207635 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207691 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207693 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207703 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207707 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207709 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207717 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207719 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207725 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207729 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207735 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207739 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207741 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207743 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207745 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207749 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207751 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207753 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207755 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207757 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207759 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207761 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207763 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207765 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207767 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207771 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207773 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207823 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208785 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208801 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208875 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184208879 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $990.00 | 06/04/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109535 |
| Principal investigator 1 | Genentech, Inc. | $63.00 | 05/23/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664261 |
| Principal investigator 1 | Genentech, Inc. | $567.00 | 05/23/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664269 |
| Principal investigator 1 | Genentech, Inc. | $891.00 | 05/23/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664278 |
| Principal investigator 1 | Genentech, Inc. | $752.00 | 05/21/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664258 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 05/21/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664273 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,005.50 | 05/21/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192163420 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,595.77 | 05/21/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046400 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,847.00 | 05/16/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046392 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $14,410.44 | 05/14/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046394 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 05/09/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046390 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $31.25 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17.50 | 05/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184193555 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/02/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601460 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $160,166.10 | 05/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185547033 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,492.70 | 04/23/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192108134 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $125,331.52 | 04/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185547003 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,747.06 | 04/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547021 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $26,561.35 | 04/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin | No dispute reported | 06/30/2026 | 1185547023 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $143.92 | 04/08/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046046 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,629.76 | 04/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547013 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,378.90 | 04/02/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109549 |
| Principal investigator 1 | CIPLA USA INC. | $875.00 | 04/01/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER, LLC | A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. | No dispute reported | 06/30/2026 | 1254932243 |
| Principal investigator 1 | CIPLA USA INC. | $3,600.00 | 04/01/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER, LLC | A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. | No dispute reported | 06/30/2026 | 1254932245 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $215.88 | 03/12/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244046044 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,880.60 | 03/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin | No dispute reported | 06/30/2026 | 1185547007 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,280.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185547029 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $48,223.00 | 03/05/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin | No dispute reported | 06/30/2026 | 1185547005 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $84,977.96 | 03/05/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185547017 |
| Principal investigator 1 | Genentech, Inc. | $3,564.00 | 02/28/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211664254 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $21,976.20 | 02/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109560 |
| Principal investigator 1 | Incyte Corporation | $1,443.60 | 02/19/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601444 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,690.77 | 02/13/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER LLC | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190309838 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,038.30 | 02/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192109520 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,747.26 | 01/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547037 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,590.16 | 01/15/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547027 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,261.37 | 01/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547011 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $34,108.43 | 01/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart | No dispute reported | 06/30/2026 | 1185547039 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $123,312.00 | 01/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185547041 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,968.82 | 01/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER, LLC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547009 |
| Principal investigator 1 | CIPLA USA INC. | $17,058.99 | 01/07/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER, LLC | A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. | No dispute reported | 06/30/2026 | 1254932241 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $48,124.28 | 01/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185547031 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $32.31 | 01/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192163415 |
| Principal investigator 1 | Incyte Corporation | $2,150.00 | 01/03/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601448 |
| Principal investigator 1 | Incyte Corporation | $3,500.00 | 01/03/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601452 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $120,830.80 | 01/02/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart | No dispute reported | 06/30/2026 | 1185547015 |
| Principal investigator 1 | Incyte Corporation | $74.34 | 01/02/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601436 |
| Principal investigator 1 | Incyte Corporation | $27.84 | 01/02/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601440 |
| Principal investigator 1 | Incyte Corporation | $251.42 | 01/02/2025 | Non-covered Recipient Entity THE CLINICAL RESEARCH CENTER CRC, LLC | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240601456 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $295.80 | 01/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190311027 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,678.04 | 01/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER LLC | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190311029 |